Proven algorithms. Premium data. Predictions you can rely on.
How to Improve Your Drug Candidate Quality Without Adding New Steps to Your Program
As every researcher in early development knows, there is constant pressure to identify high-quality drug candidates—while also increasing the speed and efficiency of the discovery process.
Navigating Synthon Space: Property-Driven Molecular Optimization for Pharmacokinetics
The Complexity of Chemical Space
AI & Adaptive Learning: A New Era in Clinical Trial Optimization, Protocol Compliance and Risk Based Monitoring
In this webinar, Dr. Brad Stefanovic, VP, Head of Clinical Innovation at Simulations Plus, discusses how biotechs and big pharma alike can stretch their clinical trials dollars while optimizing key areas for compliance and success.
Improvements in Data Quality Can Boost Efficiency and Reduce Development Costs: Findings from a Survey of Pharmacometric CROs
Modern drug development, which can take up to 15 years and cost as much as $11 billion USD, relies heavily on high-quality data1. Recognizing the criticality of attaining quality data that is easily convertible to analysis-ready datasets, a survey was developed to obtain baseline information on data quality and data standards, largely from a CRO perspective.
Quantitative Systems Toxicology (QST) Modeling Using BIOLOGXsym and Mechanistic Toxicity Data From a Biomimetic Liver Microphysiology System Predicts Biologics-induced Liver Injury
While biologics offer promise in addressing a range of unmet medical needs, clinically observed BILI events are concerning for drug developers, health care providers and patients.
ADMET Predictor® 13: Predict & Build with Confidence
ADMET Predictor 13 is almost here—and in this webinar, you’ll see how it gives your organization the First-to-Invent Advantage! Drs. David Miller, Vice President, ADMET Cheminformatics, and Michael Lawless, Sr. Principal Scientist, Cheminformatics Solutions walk you through the latest version of the software...
Predicting Brinzolamide Ocular Response in Humans Using an Ocular PBPK-PD Modeling and Simulation
The development of generic ophthalmic drug products indicated for intraocular pressure (IOP) reduction typically relies on comparative pharmacodynamic (PD) endpoint bioequivalence (BE) studies.
Intestinal Secretion Is a Potentially Important Clearance Mechanism for Low Metabolic Clearance Compounds
Intestinal excretion/secretion (IE) from the systemic circulation via the enterocytes into the intestinal lumen has traditionally been considered a minor clearance (CL) pathway.
Framework for Classifying Chemicals for Repeat Dose Toxicity Using NAMs
EPAA’s ‘NAM Designathon 2023’ challenge for human toxicity sought to identify a classification system capable of categorising chemicals based on their bioactivity and bioavailability properties determined using non-animal methodologies (Worth et al. 2025).
Multi-target Property Prediction and Optimization Using Latent Spaces of Generative Model
Multi-target property prediction has the potential to improve generalization by exploiting the positive transfer between targets.
Beyond the Lab: FDA’s Vision for Modeling a Future Without Animal Testing
The FDA has released a new roadmap outlining a path toward reducing—and ultimately replacing—animal studies in pharmaceutical development with new approach methodologies (NAMs), beginning with monoclonal antibodies.
Accessing DDI Standards in the Simulations Plus Training Portal
Your GastroPlus DDI Module license grants you access to our DDI reports and databases through the Simulations Plus Training Portal. You must register on the portal with your company email address in order to access these resources.
Simulations Plus Releases DILIsym® 11
Newest version of the quantitative systems toxicology (QST) software supports drug-induced liver injury (DILI) prediction for pediatric patient populations
Drug-Induced Liver Injury: A Look at QST Modeling and AI Predictions
As AI tools gain traction in drug development, there is growing enthusiasm around their potential to predict drug-induced liver injury (DILI).
Beyond the Linear Model in Concentration-QT Analysis
This work introduces several extensions for concentration-QT modeling in a pharmacometric context.
Smarter Clinical Development: How to Use QSP to Maximize the Value of GLP-1 Agonists
As the market for GLP-1 agonists expands, biotech companies face both immense opportunity and fierce competition. To stand out in this evolving landscape and enhance the likelihood of acquisition or out-licensing, early-stage companies must develop a strategic, data-driven clinical development plan.
A Well-Characterized Mechanistic Model for Exploring Known or Hypothesized T cell Mediated Drug Induced Liver Injury: Current Capabilities and Challenges for Future Predictivity
Drug-induced liver injury (DILI) is an adverse event whose emergence can slow or halt drug development programs.
Phasing Out Animal Testing: Responding to FDA and EMA’s Strategic Shifts
Both the U.S. Food and Drug Administration (FDA) (1) and the European Medicines Agency (EMA) (2) have articulated clear regulatory expectations for the implementation and advancement of non-animal methods, known as new approach methodologies (NAMs).
Role of Physiologically Based Biopharmaceutics Modeling in Predicting and Circumventing the Drug-Drug Interactions of Tyrosine Kinase Inhibitors with Acid-Reducing Agents
Tyrosine kinase inhibitors (TKIs) are molecular targeting agents used to treat various types of cancer. During the treatment with TKIs, acid-reducing agents (ARAs) are prescribed to prevent gastric mucosal damage.